MARTELLUCCI, IGNAZIO
 Distribuzione geografica
Continente #
NA - Nord America 1.676
EU - Europa 1.447
AS - Asia 918
SA - Sud America 123
AF - Africa 40
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.208
Nazione #
US - Stati Uniti d'America 1.642
RU - Federazione Russa 384
SG - Singapore 328
GB - Regno Unito 306
CN - Cina 275
IE - Irlanda 182
VN - Vietnam 134
IT - Italia 129
BR - Brasile 98
UA - Ucraina 88
SE - Svezia 86
FR - Francia 85
DE - Germania 80
HK - Hong Kong 72
FI - Finlandia 47
KR - Corea 29
IN - India 25
ZA - Sudafrica 24
CA - Canada 19
ES - Italia 13
BD - Bangladesh 11
MX - Messico 11
IQ - Iraq 8
NL - Olanda 8
TR - Turchia 8
BE - Belgio 7
PL - Polonia 7
VE - Venezuela 7
LT - Lituania 6
CI - Costa d'Avorio 5
IL - Israele 5
PE - Perù 5
AR - Argentina 4
CO - Colombia 4
NG - Nigeria 4
PK - Pakistan 4
AT - Austria 3
JP - Giappone 3
AO - Angola 2
AZ - Azerbaigian 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
HR - Croazia 2
IR - Iran 2
PA - Panama 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
FJ - Figi 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
ID - Indonesia 1
KI - Kiribati 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MT - Malta 1
MY - Malesia 1
PH - Filippine 1
QA - Qatar 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 4.208
Città #
Southend 262
Singapore 204
Dallas 189
Dublin 178
Fairfield 175
Ashburn 144
Moscow 100
Woodbridge 86
Chandler 84
Santa Clara 84
Beijing 83
Seattle 76
Jacksonville 72
Houston 69
Hong Kong 68
Wilmington 63
San Jose 57
Cambridge 48
Ann Arbor 44
Ho Chi Minh City 44
Siena 40
Hanoi 37
Hefei 37
New York 36
Los Angeles 32
Princeton 31
Council Bluffs 30
Munich 30
Nanjing 30
Seoul 29
Helsinki 25
Johannesburg 22
Lauterbourg 21
Milan 20
Shanghai 19
The Dalles 13
Boardman 12
San Diego 12
San Mateo 12
Florence 11
London 10
São Paulo 10
Málaga 9
Turku 8
Brussels 7
Denver 7
Montreal 7
Warsaw 7
Amsterdam 6
Chicago 6
Da Nang 6
Dearborn 6
Düsseldorf 6
Nanchang 6
Toronto 6
Abidjan 5
Baghdad 5
Bologna 5
Boston 5
Buffalo 5
Catania 5
Haiphong 5
Nuremberg 5
Orem 5
Redondo Beach 5
San Francisco 5
Abuja 4
Ankara 4
Belo Horizonte 4
Bengaluru 4
Brooklyn 4
Cagliari 4
Changsha 4
Chennai 4
Dong Ket 4
Frankfurt am Main 4
Hebei 4
Ningbo 4
Poplar 4
Renton 4
Rome 4
Aguascalientes 3
Atlanta 3
Can Tho 3
Curitiba 3
Fremont 3
Hangzhou 3
Kunming 3
Lima 3
Manchester 3
Mexico City 3
Mumbai 3
Paris 3
Phoenix 3
Stockholm 3
Tianjin 3
Tokyo 3
Vinci 3
Washington 3
Auburn Hills 2
Totale 2.907
Nome #
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients 338
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy 314
A62Effectiveness and resulting surgical behavior after neoadjuvant chemotherapy in locally advanced breast cancer: our experience 285
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients 256
Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients 251
Cisplatin, etoposide, and bevacizumab regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell lung cancer: A single-institution experience 245
Bevacizumab and weekly Doxetacel in patients with metastatic castrate-resistant prostate cancer previously exposed to Docetaxel 240
Effects of intravenous Zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from NSCLC 220
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 214
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study 209
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 209
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) 206
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients 205
First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC: a real-life setting study with gender prospective 169
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer 160
Porcelain gallbladder and its relationship to cancer 160
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractionated cisplatimum, oral etoposide, and bevacizumab 159
Sjögren's syndrome and aromatase inhibitors treatment: is there a link? 135
Head and Neck Carcinoma and biomarker profiling: searching tumor identity card. 110
Head and Neck Carcinoma and biomarker profiling: searching tumor identity card. 80
Rare variants modulating phenotype in NF1 carriers 64
Early psychological intervention in cancer patients: effects on emotional distress 29
null 3
Totale 4.261
Categoria #
all - tutte 12.747
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.747


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202190 0 0 0 0 0 0 0 0 0 34 33 23
2021/2022253 22 20 14 19 15 11 9 10 12 31 33 57
2022/2023319 21 23 47 40 27 63 5 29 33 10 14 7
2023/2024293 5 5 24 13 10 88 105 9 3 12 3 16
2024/2025600 33 27 63 38 73 33 8 19 74 27 77 128
2025/20261.600 107 189 147 232 386 97 212 66 54 110 0 0
Totale 4.261